Modular Antibody Technology
Our robust discovery engine lets us easily “mix-and-match” antibody components to create unique bispecific antibody products.
F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as “2-in-1” drugs.
News & Events
- 9 January 2015: FS102 Enters Phase 1 Clinical Trial
- 4 November 2014: F-star Creates Second Asset-Centric Vehicle, F-star Beta Ltd
- 28 October 2014: BMS Option Agreement to Acquire F-star Alpha Ltd